- Home
- BREA vs PPBT Comparison
BREA vs PPBT Comparison
Compare BREA & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- PPBT
- Stock Information
- Founded
- BREA 2022
- PPBT 2010
- Country
- BREA Ireland
- PPBT Israel
- Employees
- BREA N/A
- PPBT N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- PPBT Health Care
- Exchange
- BREA Nasdaq
- PPBT Nasdaq
- Market Cap
- BREA 13.6M
- PPBT 6.3M
- IPO Year
- BREA 2023
- PPBT N/A
- Fundamental
- Price
- BREA $7.43
- PPBT $2.37
- Analyst Decision
- BREA
- PPBT Strong Buy
- Analyst Count
- BREA 0
- PPBT 1
- Target Price
- BREA N/A
- PPBT $33.00
- AVG Volume (30 Days)
- BREA 18.9K
- PPBT 26.3K
- Earning Date
- BREA 01-03-2025
- PPBT 08-15-2025
- Dividend Yield
- BREA N/A
- PPBT N/A
- EPS Growth
- BREA N/A
- PPBT N/A
- EPS
- BREA N/A
- PPBT N/A
- Revenue
- BREA $2,988,009.00
- PPBT N/A
- Revenue This Year
- BREA N/A
- PPBT N/A
- Revenue Next Year
- BREA N/A
- PPBT N/A
- P/E Ratio
- BREA N/A
- PPBT N/A
- Revenue Growth
- BREA 151.51
- PPBT N/A
- 52 Week Low
- BREA $5.00
- PPBT $2.00
- 52 Week High
- BREA $19.50
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- BREA 57.22
- PPBT 42.59
- Support Level
- BREA $5.90
- PPBT $2.25
- Resistance Level
- BREA $7.78
- PPBT $2.45
- Average True Range (ATR)
- BREA 0.69
- PPBT 0.13
- MACD
- BREA 0.06
- PPBT -0.02
- Stochastic Oscillator
- BREA 83.82
- PPBT 21.11
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.